A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis

Inclusion Criteria

• •1. Signed informed consent must be obtained prior to participation in the study
• •2. Male or female patients aged ≥18 years at enrollment
• •3. Diagnosis of MS according to the 2017 revised McDonald criteria (Thompson et al 2018b)
• •4. RMS with active disease as defined by Lublin et al. (2014)
• •5. Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment
• •6. Disability status at enrollment with an EDSS score of 0 to 2.5 (inclusive)
• •7. Planned initiation or initiation within the past 14 days with an approved injectable DMT for MS as routine medical treatment
• •1. Signed informed consent must be obtained prior to participation,
• •2. Male or female patients aged ≥18 years at enrollment,
• •3. Diagnosis of MS according to the 2024 revised McDonald criteria (Montalban et al., 2025),
• •4. RMS with active disease as defined by Lublin et al. (2014) ,
• •5. Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment,
• •6. Disability status at enrollment with an EDSS score of 0 to 3.0 (inclusive),
• •7. Planned initiation or initiation within the past 14 days with an approved injectable or oral DMT for MS as routine medical treatment:
• •* Ofatumumab: only naïve patients or patients previously treated with max. one DMT other than ofatumumab
• •* IFN-β1, GA, teriflunomide, DMF or DRF: only naïve patients
• •4. Relapse prior to enrollment which has led to a severe deficit relevant to everyday life upon discretion of the investigator after exhaustion of the relapse therapy
• •5. Poor recovery from the first two relapses prior to enrollment upon discretion of the investigator
• •6. EDSS Functional System Score "Pyramidal Functions" ≥ 2 at enrollment
• •7. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with Ofatumumab